RG3039 (PF-06687859) is a potent and selective DcpS inhibitor developed for spinal muscular atrophy (SMA) research. It has demonstrated efficacy in preclinical studies, improving survival, motor function, and neuromuscular pathology in SMA mouse models, supporting its investigation as a potential therapeutic strategy.